18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

• Status: Completed
• Trial end date: 2019-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme (GBM), gynecological cancers, and renal cell carcinoma (RCC) who are receiving antiangiogenesis treatment.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanjiv Sam Gambhir
• Collaborator: National Cancer Institute (NCI)
• Treatments: Fluorodeoxyglucose F18; Glycine

Criteria

Inclusion Criteria:

• Provides written informed consent

• Diagnosed with advanced NSCLC, breast cancer, GBM or other cancers (such as head and neck, colorectal, pancreatic, renal cancers); patients will undergo anti-angiogenesis treatment or treatment with other drugs that may alter angiogenesis

• Able to remain still for duration of each imaging procedure (about one hour)

Exclusion Criteria:

• Pregnant or nursing

• Contraindication to MRI

• History of renal insufficiency (only for MRI contrast administration)